Global
Therapeutic potential of the endocannabinoid system in respiratory diseases
This review analysed how the endocannabinoid system regulates major pulmonary conditions, such as asthma and acute lung injury. The authors identified that modulating cannabinoid receptors or metabolic enzymes may reduce lung inflammation and support barrier integrity. Nevertheless, because these physiological responses depend heavily on specific contexts, clinical trials are necessary to confirm therapeutic efficacy.
- The endocannabinoid system helps regulate lung inflammation and maintains the integrity of the air-blood barrier.
- Targeting cannabinoid receptors and metabolic enzymes shows therapeutic potential for asthma and acute lung injury.
- Therapeutic interventions must be highly precise due to the context-dependent nature of endocannabinoid modulation.
Our view
This is mechanistic and preclinical work, and it should be read as a map of where research might go rather than as a basis for treatment. The context-dependence the authors describe is the central difficulty: the same signalling pathway can be protective or harmful depending on the state of the tissue. Translation into respiratory medicine will require selective agents and adequately powered clinical trials before any claim of efficacy can be made.
Sources
Get the latest medical cannabis news by email
We send AMI updates and research summaries once a week.
